A Study of ES104 in Patients With Metastatic Colorectal Cancer
Status:
Not yet recruiting
Trial end date:
2026-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this open-label, Multicenter Phase I/II study is to evaluate the safety,
tolerability, preliminary anti-tumor efficay, pharmacokinetics, anti-drug antibodies and
biomarkers of ES104 in patients with unresectable locally advanced or metastatic colorectal
cancer who have failed systemic therapies.